ArticleMolecular & cellular proteomics : MCP2026
Label-Free Targeted Proteomics Data Analysis Workflow Selection - Benchmarking AI-based and Data-Driven Approaches.
Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As global proteomics continues to advance, the number of identifiable proteins has increased substantially. However, this does not inherently ensure optimal quantitative performance. While targeted assays using isotope-labeled peptides can be developed, label-free strategies remain an attractive and cost-efficient option for methodological validation. Yet, systematic evaluations of data analysis workflows for label-free targeted proteomics, particularly those incorporating artificial intelligence (AI)-based tools, are still limited. Therefore, this study aimed to benchmark multiple data analysis approaches for label-free targeted proteomics as a validation framework for results obtained from global analyses. Missing-data imputation (MDI) strategies, including no MDI, k-nearest neighbors, data-driven, MSstats and AI-based methods, were evaluated, alongside consolidation and testing frameworks such as mathematical summation, best-peak selection, AI-based scaling with univariate statistics, p-value integration, MSstats Tukey's median polish or linear models and multivariate testing. Data-driven MDI combined with p-value integration consistently showed the strongest performance across accuracy, precision, specificity, and false-discovery rate, outperforming all other strategies. These findings demonstrate that careful selection of data analysis workflows can yield substantially improved quantitative outcomes compared with commonly used approaches such as simple mathematical summation. Although our conclusions are based on a controlled benchmarking dataset comprising three yeast proteins spiked into a constant human background using only one targeted approach, they can be generally applied as a default workflow for biomarker validation using the label-free approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.